Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 3.20
BIOC's Cash to Debt is ranked higher than
51% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. BIOC: 3.20 )
Ranked among companies with meaningful Cash to Debt only.
BIOC' s 10-Year Cash to Debt Range
Min: 0  Med: 2.92 Max: No Debt
Current: 3.2
Equity to Asset 0.60
BIOC's Equity to Asset is ranked higher than
50% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. BIOC: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
BIOC' s 10-Year Equity to Asset Range
Min: -18.63  Med: 0.15 Max: 0.83
Current: 0.6
-18.63
0.83
F-Score: 4
Z-Score: -9.96
M-Score: -0.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -4787.54
BIOC's Operating margin (%) is ranked lower than
97% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. BIOC: -4787.54 )
Ranked among companies with meaningful Operating margin (%) only.
BIOC' s 10-Year Operating margin (%) Range
Min: -1227100  Med: -10033.68 Max: -5928.36
Current: -4787.54
-1227100
-5928.36
Net-margin (%) -4977.00
BIOC's Net-margin (%) is ranked lower than
97% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. BIOC: -4977.00 )
Ranked among companies with meaningful Net-margin (%) only.
BIOC' s 10-Year Net-margin (%) Range
Min: -1362900  Med: -11588.52 Max: -6890.3
Current: -4977
-1362900
-6890.3
ROE (%) -224.86
BIOC's ROE (%) is ranked lower than
90% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. BIOC: -224.86 )
Ranked among companies with meaningful ROE (%) only.
BIOC' s 10-Year ROE (%) Range
Min: 0  Med: 0.00 Max: 0
Current: -224.86
ROA (%) -112.82
BIOC's ROA (%) is ranked lower than
88% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. BIOC: -112.82 )
Ranked among companies with meaningful ROA (%) only.
BIOC' s 10-Year ROA (%) Range
Min: -694.81  Med: -659.50 Max: -400.76
Current: -112.82
-694.81
-400.76
ROC (Joel Greenblatt) (%) -2434.21
BIOC's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. BIOC: -2434.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIOC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3222.72  Med: -2717.73 Max: -1614.63
Current: -2434.21
-3222.72
-1614.63
» BIOC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with BIOC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.36
BIOC's P/B is ranked lower than
52% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. BIOC: 3.36 )
Ranked among companies with meaningful P/B only.
BIOC' s 10-Year P/B Range
Min: 2.1  Med: 3.53 Max: 5.65
Current: 3.36
2.1
5.65
P/S 66.00
BIOC's P/S is ranked lower than
96% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. BIOC: 66.00 )
Ranked among companies with meaningful P/S only.
BIOC' s 10-Year P/S Range
Min: 8.02  Med: 42.78 Max: 110
Current: 66
8.02
110
EV-to-EBIT -1.70
BIOC's EV-to-EBIT is ranked lower than
251% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.91 vs. BIOC: -1.70 )
Ranked among companies with meaningful EV-to-EBIT only.
BIOC' s 10-Year EV-to-EBIT Range
Min: -3.2  Med: -1.00 Max: -0.1
Current: -1.7
-3.2
-0.1
Current Ratio 5.74
BIOC's Current Ratio is ranked higher than
79% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. BIOC: 5.74 )
Ranked among companies with meaningful Current Ratio only.
BIOC' s 10-Year Current Ratio Range
Min: 0.02  Med: 4.94 Max: 10.2
Current: 5.74
0.02
10.2
Quick Ratio 5.65
BIOC's Quick Ratio is ranked higher than
80% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. BIOC: 5.65 )
Ranked among companies with meaningful Quick Ratio only.
BIOC' s 10-Year Quick Ratio Range
Min: 0.02  Med: 4.82 Max: 10.09
Current: 5.65
0.02
10.09
Days Inventory 23.13
BIOC's Days Inventory is ranked higher than
79% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. BIOC: 23.13 )
Ranked among companies with meaningful Days Inventory only.
BIOC' s 10-Year Days Inventory Range
Min: 9.26  Med: 12.06 Max: 23.71
Current: 23.13
9.26
23.71
Days Sales Outstanding 37.32
BIOC's Days Sales Outstanding is ranked higher than
82% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. BIOC: 37.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOC' s 10-Year Days Sales Outstanding Range
Min: 24.51  Med: 46.91 Max: 1825
Current: 37.32
24.51
1825

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.96
BIOC's Price/Net Cash is ranked higher than
78% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.50 vs. BIOC: 3.96 )
Ranked among companies with meaningful Price/Net Cash only.
BIOC' s 10-Year Price/Net Cash Range
Min: 2.99  Med: 4.49 Max: 5.1
Current: 3.96
2.99
5.1
Price/Net Current Asset Value 3.66
BIOC's Price/Net Current Asset Value is ranked higher than
74% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.66 vs. BIOC: 3.66 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIOC' s 10-Year Price/Net Current Asset Value Range
Min: 2.77  Med: 3.87 Max: 4.72
Current: 3.66
2.77
4.72
Price/Tangible Book 3.36
BIOC's Price/Tangible Book is ranked higher than
64% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.24 vs. BIOC: 3.36 )
Ranked among companies with meaningful Price/Tangible Book only.
BIOC' s 10-Year Price/Tangible Book Range
Min: 2.64  Med: 3.50 Max: 4.32
Current: 3.36
2.64
4.32
Price/Median PS Value 1.71
BIOC's Price/Median PS Value is ranked lower than
86% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. BIOC: 1.71 )
Ranked among companies with meaningful Price/Median PS Value only.
BIOC' s 10-Year Price/Median PS Value Range
Min: 0.35  Med: 1.26 Max: 2.2
Current: 1.71
0.35
2.2
Earnings Yield (Greenblatt) (%) -58.80
BIOC's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. BIOC: -58.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIOC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -560.3  Med: 0.00 Max: 0
Current: -58.8
-560.3
0

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 1 4
EPS($) -1.05 -0.85
EPS without NRI($) -1.05 -0.85

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:B00.Germany,
» More Articles for BIOC

Headlines

Articles On GuruFocus.com
mbs Feb 24 2015 
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 

More From Other Websites
Keep An Eye On Monday's After-Hours Movers Aug 25 2015
BIOCEPT INC Financials Aug 22 2015
BIOCEPT INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Aug 21 2015
Biocept Announces Personnel Change Aug 21 2015
Biocept Announces Personnel Change Aug 21 2015
Biocept Could Double On Liquid Biopsy Leadership: H.C. Wainwright Aug 19 2015
Coverage initiated on Biocept by H.C. Wainwright Aug 19 2015
BIOCEPT INC Files SEC form 10-Q, Quarterly Report Aug 11 2015
Biocept and University of California, Irvine to Study Blood-based Liquid Biopsy Testing in Cancer... Aug 11 2015
Biocept and University of California, Irvine to Study Blood-based Liquid Biopsy Testing in Cancer... Aug 11 2015
BIOCEPT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 10 2015
Biocept Reports Second Quarter 2015 Financial Results Aug 10 2015
Biocept Reports Second Quarter 2015 Financial Results Aug 10 2015
Biocept Launches its First Liquid Biopsy Diagnostic Test for Colorectal Cancer Aug 05 2015
Biocept Launches its First Liquid Biopsy Diagnostic Test for Colorectal Cancer Aug 05 2015
Biocept to Hold 2015 Second Quarter Conference Call on August 10 Aug 03 2015
Biocept to Hold 2015 Second Quarter Conference Call on August 10 Aug 03 2015
Dr. Marileila Varella Garcia Joins Biocept as Scientific Advisor Aug 03 2015
Dr. Marileila Varella Garcia Joins Biocept as Scientific Advisor Aug 03 2015
Biocept Announces Presentation at Next Generation Dx Summit Jul 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK